These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20229169)

  • 1. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.
    Akagi J; Baba H
    Int J Clin Oncol; 2010 Apr; 15(2):145-52. PubMed ID: 20229169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
    Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
    Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M
    Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1).
    Namikawa T; Fukudome I; Ogawa M; Munekage E; Munekage M; Shiga M; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Eur J Surg Oncol; 2015 Jun; 41(6):795-800. PubMed ID: 25887287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
    Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subset analysis of preoperative lymphocyte ratio in stage II or III colorectal cancer patients treated with oral tegafur-uracil and protein-bound polysaccharide K].
    Totsuka O; Kawate S; Hirai K; Ogawa H; Toya H; Yoshinari D; Sunose Y; Takeyoshi I
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2525-8. PubMed ID: 24335363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study.
    Ohwada S; Ikeya T; Yokomori T; Kusaba T; Roppongi T; Takahashi T; Nakamura S; Kakinuma S; Iwazaki S; Ishikawa H; Kawate S; Nakajima T; Morishita Y
    Br J Cancer; 2004 Mar; 90(5):1003-10. PubMed ID: 14997197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2016 Aug; 36(8):4237-41. PubMed ID: 27466538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
    Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
    Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
    J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
    Yoshitani S; Takashima S
    Cancer Biother Radiopharm; 2009 Feb; 24(1):35-40. PubMed ID: 19243246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).
    Okuno K; Aoyama T; Oba K; Yokoyama N; Matsuhashi N; Kunieda K; Nishimura Y; Akamatsu H; Kobatake T; Morita S; Yoshikawa T; Sakamoto J; Saji S
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):65-71. PubMed ID: 29094178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
    Yen HH; Chen CN; Yeh CC; Lai IR
    World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
    Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
    Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer.
    Akagi J; Baba H
    Int J Clin Oncol; 2008 Dec; 13(6):528-35. PubMed ID: 19093181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regression of metastatic hepatic cancer from gastric cancer by polysaccharide K and UFT administration--a case report].
    Ohashi Y; Watanabe M; Ikeda M; Nanami T; Yamazaki K; Yajima S; Oshima Y; Takeyama T; Ito M; Saito F
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2409-12. PubMed ID: 19098413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy of gastric cancer with oral UFT (a mixture of uracil and fturafur) during the waiting period for surgery.
    Nio Y; Sato Y; Nagami H; Teramoto M; Inoue Y; Yano S; Sumi S; Tamura K; Fukumoto M
    Anticancer Res; 1998; 18(1B):523-30. PubMed ID: 9568172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.
    Sugimachi K; Maehara Y; Ogawa M; Kakegawa T; Tomita M
    Cancer Chemother Pharmacol; 1997; 40(3):233-8. PubMed ID: 9219507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.